|Application ||WB, FC, E|
|Calculated MW||85035 Da|
|Antigen Region||538-567 aa|
|Other Names||Discoidin, CUB and LCCL domain-containing protein 2, CUB, LCCL and coagulation factor V/VIII-homology domains protein 1, Endothelial and smooth muscle cell-derived neuropilin-like protein, DCBLD2, CLCP1, ESDN|
|Target/Specificity||This DCBLD2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 538-567 amino acids from the C-terminal region of human DCBLD2.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||DCBLD2 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Cellular Location||Membrane; Single-pass type I membrane protein|
|Tissue Location||Highly expressed in testis, heart, skeletal muscle and also in cultured vascular smooth muscle cells|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
DCBLD2, otherwise known as ESDN (endothelial and smooth muscle cell-derived neuropilin-like molecule) is a novel type-I transmembrane protein with the longest cleavable secretory signal sequence among eukaryotes. It is expressed in various tissues; particularly highly expressed in cultured vascular smooth muscle cells. DCBLD2 is considered to play a role in regulation of vascular cell growth and may have a wide variety of functions in other tissues including the nervous system, like neuropilins.
Rose, J. Phd, et al. Mol. Med. (2010) In press :
Guo, X., et al. J. Biol. Chem. 284(43):29376-29382(2009)
Marroni, F., et al. Circ Cardiovasc Genet 2(4):322-328(2009)
Kim, M., et al. Mol. Cancer Res. 6(2):222-230(2008)
Sadeghi, M.M., et al. Am. J. Transplant. 7(9):2098-2105(2007)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.